| Literature DB >> 22099086 |
Akihisa Okumura1, Satoshi Nakagawa, Hisashi Kawashima, Takashi Muguruma, Osamu Saito, Jun-ichi Fujimoto, Chiaki Toida, Shuji Kuga, Toshihiro Imamura, Toshiaki Shimizu, Naomi Kondo, Tsuneo Morishima.
Abstract
To clarify the cause of deaths associated with pandemic (H1N1) 2009 among children in Japan, we retrospectively studied 41 patients <20 years of age who had died of pandemic (H1N1) 2009 through March 31, 2010. Data were collected through interviews with attending physicians and chart reviews. Median age of patients was 59 months; one third had a preexisting condition. Cause of death was categorized as unexpected cardiopulmonary arrest for 15 patients, encephalopathy for 15, and respiratory failure for 6. Preexisting respiratory or neurologic disorders were more frequent in patients with respiratory failure and less frequent in patients with unexpected cardiopulmonary arrest. The leading causes of death among children with pandemic (H1N1) 2009 in Japan were encephalopathy and unexpected cardiopulmonary arrest. Deaths associated with respiratory failure were infrequent and occurred primarily among children with preexisting conditions. Vaccine use and public education are necessary for reducing influenza-associated illness and death.Entities:
Mesh:
Year: 2011 PMID: 22099086 PMCID: PMC3311116 DOI: 10.3201/eid1711.110649
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Causes of death for 41 patients <20 years of age with pandemic (H1N1) 2009, Japan, May 2009–March 2010
| Cause | Definition |
|---|---|
| Unexpected cardiopulmonary arrest | Cardiopulmonary arrest without clear findings of respiratory failure, cardiomyopathy, or encephalopathy |
| Respiratory failure | Desaturation, need for oxygen supplementation or mechanical ventilation or both, associated with radiologic findings of pneumonia or acute lung injury |
| Myocarditis | Markedly reduced cardiac output, severe and refractory arrhythmia, or severe circulatory collapse |
| Viral sepsis | Refractory hypotension and rapidly progressing multiorgan failure associated with at least 2 of the following: tachypnea; leukopenia <4000 cells/μL or leukocytosis >12,000 cells/μL; tachycardia; body temperature >38.0°C or <36.0°C; cold extremities; and increased capillary refill time |
| Encephalopathy | At least 1 of the following: altered mental state without profound respiratory and cardiac failure or neuroimaging findings consistent with encephalopathy such as marked brain edema, focal lesions, and blurred gray-white matter junction |
| Incidental | Other findings that are not directly attributable to influenza infection |
Figure 1Timing of onset of pandemic (H1N1) 2009 in children and patient age, Japan, May 2009–March 2010. A) Date of illness onset for children >15 years of age compared with those <15 years of age. B) No. patients at each age at time of illness onset.
Figure 2Days from onset of pandemic (H1N1) 2009 illness to A) life-threatening event or B) death among patients <20 years of age, Japan, May 2009–March 2010.
Comparisons by cause of death among patients <20 years of age, Japan, May 2009–March 2010*
| Characteristic | Unexpected CPA, n = 15† | Encephalopathy, n = 15† | Respiratory failure, n = 6† | p value |
|---|---|---|---|---|
| Median age, mo (range) | 43 (7–164) | 62 (17–200) | 78 (45–206) | 0.053 |
| Male sex, no. (%) patients | 9 (60) | 10 (67) | 2 (33) | NS |
| Preexisting condition, no. (%) patients | ||||
| Any | 1 (7)‡ | 5 (33) | 5 (83)§ | <0.05 |
| Respiratory disorders | 0‡ | 3 (20) | 4 (67)§ | <0.05 |
| Neurologic disorders | 1 (7)‡ | 3 (20) | 5 (83)§ | <0.05 |
| Previous history of febrile seizures | 2 (13) | 3 (20) | 0 | NS |
| Days from influenza onset to life-threatening event (range) | 1 (0–9) | 1 (0–2) | 1 (0–9) | NS |
| Days from influenza onset to death (range) | 1 (0–9) | 3 (0–45) | 1.5 (1–11) | <0.05¶ |
| Clinical signs, no. (%) patients | ||||
| Cough | 5 (36), n = 14 | 11 (73) | 3 (50) | NS |
| Rhinorrhea | 4 (29), n = 14 | 7 (47) | 1 (17) | NS |
| Tachypnea or dyspnea | 1 (7), n = 14 | 4 (27) | 3 (50) | NS |
| Wheezing | 1 (7), n = 14 | 1 (7) | 2 (33) | NS |
| Vomiting or diarrhea | 2 (14), n = 14 | 5 (33) | 0 | NS |
| Drugs received before life-threatening event, no. (%) patients | ||||
| Oseltamivir | 7 (47) | 6 (40) | 5 (83) | NS |
| Zanamivir | 1 (7) | 2 (13) | 2 (33) | NS |
| Acetaminophen | 3 (30), n = 10 | 7 (50), n = 14 | 2 (40), n = 5 | NS |
| Leukocyte count, cells/μL, median (range) | 6,600 (4,200–11,100), n = 11 | 9,350 (3,100–28,730), n = 14 | 10,500 (8,650–101,200), n = 5 | NS |
| Platelet count, × 104 cells/μL, median (range) | 20.5 (11.4–45.8), n = 11 | 15.1 (6.2–32.2) | 11.5 (8.4–49.0), n = 5 | NS |
| Aspartate aminotransferase, IU/L, median (range) | 248 (55–1,981), n = 12 | 233 (18–1,760) | 52 (34–73), n = 4 | 0.060 |
| Alanine transaminase, IU/L, median (range) | 157 (32–845), n = 12 | 70 (9–1,058) | 26 (16–57), n = 4 | <0.05¶ |
| Lactate dehydrogenase, IU/L, median (range) | 704 (215–4,801), n = 12 | 899 (160–3,610), n = 14 | 535 (222–1,022), n = 4 | NS |
| Creatine kinase, IU/L, median (range) | 302 (136–10,612), n = 12 | 190 (63–1,026), n = 14 | 64 (16–211), n = 4 | <0.01# |
| Blood urea nitrogen, mg/dL, median (range) | 11.2 (7.0–31.0), n = 12 | 22.5 (11.7–40.0), n = 14 | 10.0 (4.0–15.0), n = 4 | <0.01** |
| Creatinine, mg/dL, median (range) | 0.65 (0.17–1.40), n = 12 | 1.01 (0.62–1.39) | 0.25 (0.08–1.00), n = 4 | <0.05** |
*CPA, cardiopulmonary arrest; NS, not significant. †n is for all values unless indicated otherwise. ‡Percentage significantly lower than for the other groups. §Percentage significantly higher than for the other groups. ¶p<0.05 unexpected CPA vs. encephalopathy. #p<0.05 unexpected CPA vs. respiratory failure. **p<0.01 unexpected CPA vs. encephalopathy; p<0.05 respiratory failure vs. encephalopathy.
| 1. The activity supported the learning objectives. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |
| 2. The material was organized clearly for learning to occur. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |
| 3. The content learned from this activity will impact my practice. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |
| 4. The activity was presented objectively and free of commercial bias. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |